A Trial Using Double-Bolus THR-100 Versus Streptokinase
This novel fibrinolytic agent is a 136 amino acid single chain protein secreted by some strains of Staphylococcus aureus and readily produced by recombinant DNA technology. Two natural variants of recombinant staphylokinase, THR-100 and SakSTAR, have been developed for investigational use in preliminary trials. Like SK, it forms an equimolar complex with plasmin which in turn activates plasminogen to plasmin. Unlike SK, the complexed, activated molecule (which undergoes proteolytic cleavage of the first ten amino acids to generate active staphylokinase) has a high degree of fibrin-selectivity in a human plasma milieu. This fibrin-selectivity is due in large measure to potent activation at the clot surface by trace amounts of plasmin, and rapid inactivation of the circulating complex by antiplasmin. Hence, it provides an interesting and promising alternative therapy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Prospective Phase III Parallel, Randomised Controlled Trial Using Double-bolus Recombinant Staphylokinase (THR-100) vs Streptokinase in Patients With Acute Myocardial Infarction|
- To demonstrate efficacy of THR100 as compared with streptokinase by assessment of 12-lead Electrocardiogram, specific cardiac Enzymes levels, pain relief and TIMI-90. (Non-Inferiority study) [ Time Frame: up to 4 weeks ] [ Designated as safety issue: Yes ]12-lead Electrocardiogram, ≥50% resolution of ST segment in single ECG lead of maximum deviation present at 90 minutes and 24 hours after start of thrombolytic therapy.
- To evaluate the safety profile of THR-100 in comparison with Streptokinase [ Time Frame: up to 4 weeks ] [ Designated as safety issue: Yes ]Assessment of net clinical benefit, defined as reduced mortality, non-fatal stroke, clinically-evident intracranial hemorrhage, or recurrent myocardial infarction at thirty (30) days.
|Study Start Date:||October 2010|
|Study Completion Date:||August 2011|
|Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
Experimental: Test - THR-100
120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
Other Name: Staphylokinase
Active Comparator: Streptokinase
120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
Other Name: Streptase
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01305226
|Bangalore, Karnataka, India, 560 099|
|Sri Jayadeva Institute of Cardiology.|
|Bangalore, Karnataka, India, 560 069|
|Lotus Super speciality Hospita|
|Agra, Uttar Pradesh, India, 282 002|
|Institute of Post Graduate Medical Education and Research (IPGMER)|
|Kolkatta, West Bengal, India, 700 020|
|Study Director:||Dr.A Singh, MBBS, MD||Bharat Biotech Int. Ltd.|